20.11.2018 | Globes
The firm represented BioBlast Pharma in its merger with Enlivex.
The firm has proudly represented BioBlast Pharma, from its inception as a start-up, through its US IPO process on the Nasdaq in 2014, to this day.
The head of the firm’s international law department, Shy Baranov, and Adv. Howard Berkenblit, David Huberman, Adi Israel and Boaz Shiffman represented the company.